Extended Data Fig. 1: Part A outcome data.
From: Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
a. Immunohistochemistry staining of participant O-01 pre- and post-safusidenib treatment (mIDH-R132H, ATRX, GFAP, P53, Ki67) and Hematoxylin and Eosin (H&E) stain. Scale, 50 µm. Representative of immunohistochemistry staining across n = 10 participants. b. LGG RANO values from participants through Part A of the study. c. Percent change in tumor size pre- and post-safusidenib treatment according to LGG-RANO or volumetric assessment. d. Volumetric analysis of tumor volume (cm3) for T2/FLAIR sequences in each participant over time in Part B of the study. e. LGG RANO values from participants through Part B of study. f. Swimmer plot depicting response assessment by LGG-RANO in months post biopsy. Triangles indicate surgical procedures and circles indicate study status. PD refers to progressive disease and SD refers to stable disease. Safusidenib treatment periods are depicted by solid colored lines, and arrowheads indicate ongoing treatment. Note that breaks in the x-axis indicate non-continuous intervals. g. Research Participant Perception Survey (RPPS) results from n = 8 participants who completed the survey.
